Oxford BioMedica Plc (OXB):企業の財務・戦略的SWOT分析

◆英語タイトル:Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH7057FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Oxford BioMedica Plc (OXB) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oxford BioMedica plc (Oxford Biomedica) is a biopharmaceutical company involved in the development and commercialization of gene-based medicines. It has LentiVector, a sector leading lentiviral vector delivery platform. Based on this platform the company has developed a portfolio of gene and cell therapy product candidates in ophthalmology, oncology, central nervous system (CNS) and other therapy areas. It has partnership and license agreement with other companies to develop potential gene and cell therapy products. The company has presence in different locations in Oxfordshire, the UK. Oxford BioMedica is headquartered in Oxford, the UK.

Oxford BioMedica Plc Key Recent Developments

Nov 23,2020: Oxford Biomedica appoints Dr. Sam Rasty as Non-Executive Director
Oct 06,2020: Oxford Biomedica receives MHRA approval for fourth manufacturing suite in Oxbox
Sep 17,2020: Oxford Biomedica : Interim results for the six months ended 30 June2020
Aug 03,2020: Oxford Biomedica signs Development, Manufacture & License Agreement with Beam Therapeutics for LentiVector Platform for next generation CAR-T therapeutics
Jun 01,2020: Oxford Biomedica appoints Dr. Roch Doliveux as non-executive chairman

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Oxford BioMedica Plc – Key Facts
Oxford BioMedica Plc – Key Employees
Oxford BioMedica Plc – Key Employee Biographies
Oxford BioMedica Plc – Major Products and Services
Oxford BioMedica Plc – History
Oxford BioMedica Plc – Company Statement
Oxford BioMedica Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Oxford BioMedica Plc – Business Description
Other Break-up: Bioprocessing/Commercial Development
Performance
Other Break-up: Licence Fees & Incentives
Performance
Other Break-up: Platform
Overview
Performance
Other Break-up: Product
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Rest of world
Performance
Oxford BioMedica Plc – Corporate Strategy
Oxford BioMedica Plc – SWOT Analysis
SWOT Analysis – Overview
Oxford BioMedica Plc – Strengths
Oxford BioMedica Plc – Weaknesses
Oxford BioMedica Plc – Opportunities
Oxford BioMedica Plc – Threats
Oxford BioMedica Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Oxford BioMedica Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 23, 2020: Oxford Biomedica appoints Dr. Sam Rasty as Non-Executive Director
Oct 06, 2020: Oxford Biomedica receives MHRA approval for fourth manufacturing suite in Oxbox
Sep 17, 2020: Oxford Biomedica : Interim results for the six months ended 30 June2020
Aug 03, 2020: Oxford Biomedica signs Development, Manufacture & License Agreement with Beam Therapeutics for LentiVector Platform for next generation CAR-T therapeutics
Jun 01, 2020: Oxford Biomedica appoints Dr. Roch Doliveux as non-executive chairman
May 13, 2020: Oxford Biomedica receives MHRA approval for the first two manufacturing suites in Oxbox
May 06, 2020: Oxford Biomedica: Preliminary results for the year ended 31 December 2019
Mar 18, 2020: Oxford Biomedica : Business update
Dec 19, 2019: Oxford Biomedica extends commercial supply agreement by five years for manufacture of lentiviral vectors
Sep 04, 2019: Oxford Biomedica: Interim results for the six months ended 30 June 2019
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Oxford BioMedica Plc, Key Facts
Oxford BioMedica Plc, Key Employees
Oxford BioMedica Plc, Key Employee Biographies
Oxford BioMedica Plc, Major Products and Services
Oxford BioMedica Plc, History
Oxford BioMedica Plc, Other Locations
Oxford BioMedica Plc, Subsidiaries
Oxford BioMedica Plc, Key Competitors
Oxford BioMedica Plc, Ratios based on current share price
Oxford BioMedica Plc, Annual Ratios
Oxford BioMedica Plc, Annual Ratios (Cont...1)
Oxford BioMedica Plc, Annual Ratios (Cont...2)
Oxford BioMedica Plc, Interim Ratios
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Oxford BioMedica Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Oxford BioMedica Plc (OXB):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sumitomo Corp (8053):電力:M&Aディール及び事業提携情報
    Summary Sumitomo Corp (Sumitomo) is a multifaceted business enterprise. It operates various businesses such as metal products, transportation, construction systems, infrastructure, media, network & lifestyle retail, general products, real estate, financial services, logistics, mineral resources and …
  • Ashok Leyland Limited:企業の戦略・SWOT・財務分析
    Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report Summary Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • BioLineRx Ltd (BLRX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company focuses mainly on cancer and immunology. Its’s product pipeline includes BL-8040, a short peptide …
  • Archer Ltd (ARCHER):企業の財務・戦略的SWOT分析
    Archer Ltd (ARCHER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • The SPAR Group Limited:戦略・SWOT・企業財務分析
    The SPAR Group Limited - Strategy, SWOT and Corporate Finance Report Summary The SPAR Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Neuland Laboratories Ltd (NEULANDLAB)-製薬・医療分野:企業M&A・提携分析
    Summary Neuland Laboratories Ltd (Neuland Lab), a subsidiary of Neuland Health Sciences Pvt Ltd is an API manufacturing service provider that manufactures active pharmaceutical ingredients, advanced intermediates; and offers chemistry related services. The company offers APIs in various therapeutic …
  • Leprino Foods Company:企業の戦略・SWOT・財務情報
    Leprino Foods Company - Strategy, SWOT and Corporate Finance Report Summary Leprino Foods Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Finastra Group Holdings Limited:企業の戦略・SWOT・財務情報
    Finastra Group Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Finastra Group Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • MDF Instruments Direct, Inc.:企業の戦略的SWOT分析
    MDF Instruments Direct, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • MaRS Innovation:医療機器:M&Aディール及び事業提携情報
    Summary MaRS Innovation (MaRS) is a not for profit organization that offers advisory services. The organization’s services include intellectual property, strategy development, business development, operational, marketing resources, project management, financial management, human resources, and inves …
  • Verbund AG (VER):電力:M&Aディール及び事業提携情報
    Summary Verbund AG (Verbund) is an electricity utility that generates, transmits, trades, and distributes electricity. It generates from renewable energy sources such as hydropower, biomass, wind, and solar power. The company constructs, operates and maintains power plants; trades electricity and ga …
  • Ra Medical Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ra Medical Systems Inc (Ra Medical Systems) is a medical device company that develops, designs, and commercializes excimer laser systems for the treatment of cardiovascular and dermatologic diseases. The company’s technology provides operational versatility and dose customization. Its produc …
  • ROHM Co Ltd (6963):企業の財務・戦略的SWOT分析
    ROHM Co Ltd (6963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Enmax Corporation-エネルギー分野:企業M&A・提携分析
    Summary ENMAX Corporation (ENMAX), a subsidiary of City of Calgary, is a vertically integrated energy company that generates, transmits and distributes electricity; supplies natural gas; and provides value-added services. Through its subsidiaries, the company undertakes deregulated electricity gener …
  • Ducommun Incorporated:企業の戦略・SWOT・財務情報
    Ducommun Incorporated - Strategy, SWOT and Corporate Finance Report Summary Ducommun Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • L.L. Bean, Inc.:企業の戦略・SWOT・財務情報
    L.L. Bean, Inc. - Strategy, SWOT and Corporate Finance Report Summary L.L. Bean, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • MYR Group Inc (MYRG):企業の財務・戦略的SWOT分析
    Summary MYR Group Inc (MYR Group) is an electrical contractor that provides specialty contracting services for industrial, commercial, and electrical infrastructure markets. The company operates substations, transmission lines, and distribution systems. It offers services such as distribution constr …
  • MasterCard Incorporated:企業のM&A・事業提携・投資動向
    MasterCard Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MasterCard Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Bio-Images Drug Delivery Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Bio-Images Drug Delivery Ltd (BDD) is an independent company that focuses on the development of modified and controlled release oral formulations. The company provides formulation development, troubleshooting, in vitro and in vivo testing and full technology transfer programs. It offers wide …
  • Cleco Corporate Holdings, LLC:戦略・SWOT・企業財務分析
    Cleco Corporate Holdings, LLC - Strategy, SWOT and Corporate Finance Report Summary Cleco Corporate Holdings, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆